Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + anti-CTLA4
- Development stage
- Unknown
- Lead developer
- Rambam Health Care Campus
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy involves the use of cannabidiol (CBD), a non-psychoactive phytocannabinoid, in conjunction with a monoclonal antibody targeting the Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) checkpoint. CBD is investigated for its potential to modulate the tumor microenvironment and mitigate side effects of immunotherapy, although some clinical evidence suggests it may interfere with the efficacy of immune checkpoint inhibitors (ICIs). Anti-CTLA-4 antibodies, such as ipilimumab, work by blocking the inhibitory signal on T cells, thereby enhancing the anti-tumor immune response. The combination is primarily explored in the context of advanced malignancies to either improve therapeutic outcomes or manage treatment-related toxicities.
- Other names
- CBD plus CTLA-4 inhibitorcannabidiol plus ipilimumab
02
Targets
CNR1 (Cannabinoid receptor 1)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)GABRR (GABA-A receptor subunit rho)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on cannabidiol + anti-CTLA4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + anti-CTLA4.